Novavax Inc. Stock Underperforms Monday When Compared To Competitors

CAE Inc

Change company Symbol lookup

Select an option...

CAE CAE Inc

YMAB Y-mAbs Therapeutics Inc

VINE Fresh Vine Wine Inc

BURU NUBURU Inc

AMPX Amprius Technologies Inc

CKPT Checkpoint Therapeutics Inc

IR Ingersoll Rand Inc

AVID Avid Technology Inc

VTSI VirTra Inc

UHAL U-Haul Holding Co

Industrials : Aerospace & Defense | Mid Cap Growth
Based in Canada

Company profile

CAE Inc. is a Canada-based technology company. The Company operates through three segments: Civil Aviation, Defense and Security, and Healthcare. The Civil Aviation training segment provides comprehensive training solutions for flight, cabin, maintenance and ground personnel in commercial, business and helicopter aviation, a complete range of flight simulation training devices, ab initio pilot training and crew sourcing services, as well as end-to-end digitally enabled crew management, training operations solutions and optimization software. The defense and Security segment provides training and simulation pure play focusing on ensuring mission readiness by integrating systems and solutions across all five domains for government organizations responsible for public safety. Healthcare segment provides healthcare students and clinical professionals innovative, integrated and virtual education and training solutions, including interventional and imaging simulations and curricular.

Novavax Inc. Stock Underperforms Monday When Compared To Competitors

5:14 pm ET February 6, 2023 (MarketWatch) Print

This article was automatically generated by MarketWatch using technology from Automated Insights.

Shares of Novavax Inc. (NVAX) slipped 1.25% to $11.09 Monday, on what proved to be an all-around grim trading session for the stock market, with the NASDAQ Composite Index falling 1.00% to 11,887.45 and Dow Jones Industrial Average falling 0.10% to 33,891.02. This was the stock's second consecutive day of losses. Novavax Inc. closed $90.30 short of its 52-week high ($101.39), which the company reached on February 7th.

The stock underperformed when compared to some of its competitors Monday, as Johnson & Johnson (JNJ) fell 0.76% to $163.36, Pfizer Inc. (PFE) fell 0.68% to $43.76, and Merck & Co. Inc. (MRK) rose 1.06% to $104.03. Trading volume (4.1 M) remained 3.5 million below its 50-day average volume of 7.5 M.

Data source: Dow Jones Market Data, FactSet. Data compiled February 6, 2023.

(END) Dow Jones Newswires

February 06, 2023 17:14 ET (22:14 GMT)